scispace - formally typeset
Open AccessJournal ArticleDOI

The Sodium Iodide Symporter and Its Potential Role in Cancer Therapy

TLDR
After NIS was cloned, several studies in FRTL-5 cells and cultured human thyroid cells showed that treatment with TSH stimulates iodide transport activity as well as NIS gene and protein expression, suggesting that TSH regulates NIS expression through the cAMP signal transduction pathway.
Abstract
Active transport of iodide into the thyroid gland is a crucial and rate-limiting step in the biosynthesis of thyroid hormones that play an important role in the metabolism, growth, and maturation of a variety of organ systems, in particular the nervous system (1) Although it has been known for decades that iodide transport into the thyroid gland is mediated by a specific sodium-dependent iodide transporter located at the basolateral membrane of thyroid follicular cells, the sodium iodide symporter (NIS) gene was cloned just 4 yr ago (2, 3) After cloning of the rat sodium iodide symporter (rNIS) from a Fisher rat thyroid line (FRTL-5)derived complementary DNA (cDNA) library (2), the human sodium iodide symporter (hNIS) was cloned from a human thyroid cDNA library in 1996 (3) The hNIS gene is localized on chromosome 19p12–132 and encodes a glycoprotein of 643 amino acids (aa) with a molecular mass of approximately 70–90 kDa The coding region of hNIS contains 15 exons interrupted by 14 introns and codes for a 39-kb messenger ribonucleic acid (mRNA) transcript (4) As a member of the sodium-dependent transporter family, NIS is an intrinsic membrane protein with 13 putative transmembrane domains, an extracellular amino-terminus, and an intracellular carboxyl-terminus The NIS protein has three potential Nlinked glycosylation sites; 1 is located in the fourth extracellular (seventh extramembranous domain), and 2 are located in the last extracellular (13th extramembranous domain) loop (5) (Fig 1) NIS cotransports two sodium ions along with one iodide ion, with the transmembrane sodium gradient serving as the driving force for iodide uptake The sodium gradient providing the energy for this transfer is generated by the ouabain-sensitive Na/K-adenosine triphosphatase (Na/ K-ATPase) NIS-mediated iodide transport is, therefore, inhibited by the Na/K-ATPase inhibitor ouabain as well as by the competitive inhibitors thiocyanate and perchlorate (1) (Fig 2) After active transport across the basolateral membrane of thyroid follicular cells, iodide is translocated across the apical membrane by pendrin, the Pendred syndrome gene product, which is a chloride/iodide transporter (6–10) (Fig 2) Other apical anion transporters may also be involved At the cell/colloid interface iodide is organified in a complex reaction involving oxidation catalyzed by thyroid peroxidase (TPO) and incorporation into tyrosyl residues along the thyroglobulin (Tg) backbone The thyroid hormones T3 and T4 are synthesized by coupling of two iodotyrosine residues and are stored in the colloid (Fig 2) The iodide organification step can be inhibited by propylthiouracil and methimazole, which are TPO enzyme inhibitors All of these steps are stimulated through pituitary-derived TSH, which interacts with the TSH receptor at the basolateral membrane of thyroidal cells (1) It has been known for many years that TSH stimulates iodide transport into the thyroid gland via the adenylate cyclase-cAMP pathway (1) After NIS was cloned, several studies in FRTL-5 cells and cultured human thyroid cells showed that treatment with TSH stimulates iodide transport activity as well as NIS gene and protein expression (11, 12) Forskolin and dibutyryl cAMP are able to mimic this stimulatory effect on both iodide transport activity as well as NIS gene and protein expression, suggesting that TSH regulates NIS expression through the cAMP signal transduction pathway (11) (Fig 2) In addition to its key role in thyroid physiology, NISmediated iodide accumulation in the thyroid gland is a crucial prerequisite for diagnostic scintigraphic imaging as well as for the highly efficient radioiodine therapy of benign and malignant thyroid diseases The purpose of this review is to summarize and discuss the current knowledge of NIS and its diagnostic and therapeutic implications in thyroidal and nonthyroidal cancer

read more

Citations
More filters
Journal ArticleDOI

Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

TL;DR: Today, cancer research is always aimed at the study and development of new therapeutic approaches for cancer treatment, and several researchers are focused on the development of cell therapies, anti-tumor vaccines, and new biotechnological drugs that have already shown promising results in preclinical studies, therefore, in the near future, it will certainly assist to a new revolution in the field of medical oncology.
Journal ArticleDOI

Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches

TL;DR: Despite multimodality approaches, ATC still carries a dismal prognosis and should provoke innovative strategies beyond conventional methods to tackle this uniformly lethal disease.
Journal Article

Sodium iodide symporter: its role in nuclear medicine.

TL;DR: It is proposed that NIS may serve as an alternative imaging reporter gene in addition to the HSVtk and dopaminergic receptor genes to enable these cells to concentrate iodide from plasma and in so doing offer the possibility of radioiodine therapy.
Journal ArticleDOI

A perspective view of sodium iodide symporter research and its clinical implications

TL;DR: NIS offers the unique advantage that it can be used both as a reporter and as a therapeutic gene, so that it is possible to image, monitor, and treat the tumor with radioiodide, just as in differentiated thyroid cancer.
Journal ArticleDOI

Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene.

TL;DR: The potential of the human NIS gene (hNIS) as a reporter gene is demonstrated and hNIS expression was monitored by PET after intravenous injection of (124)I, demonstrating the potential of this approach for noninvasive imaging.
References
More filters
Journal ArticleDOI

Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

TL;DR: Following 131I therapy, whether given for thyroid remnant ablation or cancer therapy, recurrence and the likelihood of cancer death were reduced by at least half, despite the existence of more adverse prognostic factors in patients given 131I.
Journal ArticleDOI

Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS)

TL;DR: These studies provide compelling evidence that defects in pendrin cause Pendred syndrome thereby launching a new area of investigation into thyroid physiology, the pathogenesis of congenital deafness and the role of altered sulphate transport in human disease.
Journal ArticleDOI

Cloning and characterization of the thyroid iodide transporter.

TL;DR: To the authors' knowledge, this is the first iodide-transporting molecule to have its cDNA cloned, providing a missing link in the thyroid hormone biosynthetic pathway.
Journal ArticleDOI

The Pendred syndrome gene encodes a chloride-iodide transport protein.

TL;DR: It is demonstrated that pendrin functions as a transporter of chloride and iodide, but not sulfate, and may provide insight into thyroid physiology and the pathophysiology of Pendred syndrome.
Journal ArticleDOI

The thyroid : a fundamental and clinical text

TL;DR: This book is an important reference text on the thyroid gland for workers in a wide variety of disciplines and will be disappointing to doctors currently setting up in vitro laboratory techniques for nuclear medicine.
Related Papers (5)